Compare CLW & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | NNNN |
|---|---|---|
| Founded | 1926 | 2021 |
| Country | United States | Germany |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 340.2M |
| IPO Year | 2008 | 2023 |
| Metric | CLW | NNNN |
|---|---|---|
| Price | $19.40 | $6.18 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.33 | N/A |
| AVG Volume (30 Days) | 109.0K | ★ 241.6K |
| Earning Date | 04-28-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $5.13 |
| 52 Week High | $23.59 | $51.33 |
| Indicator | CLW | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 40.72 |
| Support Level | $19.25 | $5.13 |
| Resistance Level | $20.80 | $12.10 |
| Average True Range (ATR) | 0.83 | 0.53 |
| MACD | -0.18 | 0.19 |
| Stochastic Oscillator | 3.91 | 57.69 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).